Alvotech (NASDAQ:ALVO) Sets New 12-Month Low After Analyst Downgrade

Shares of Alvotech (NASDAQ:ALVO) reached a new 52-week low on Wednesday after UBS Group lowered their price target on the stock from $10.00 to $6.00. UBS Group currently has a buy rating on the stock. Alvotech traded as low as $3.03 and last traded at $3.13, with a volume of 1133730 shares traded. The stock had previously closed at $3.33.

Several other analysts also recently commented on the stock. Morgan Stanley set a $10.00 target price on shares of Alvotech in a research report on Wednesday, December 3rd. Zacks Research upgraded shares of Alvotech from a “strong sell” rating to a “hold” rating in a report on Thursday, March 19th. Barclays cut their price objective on Alvotech from $5.00 to $4.00 and set an “underweight” rating on the stock in a research note on Tuesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alvotech in a report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.60.

Alvotech News Roundup

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: UBS reiterated a Buy on ALVO and cut its price target from $10 to $6, framing regulatory setbacks as largely priced in while pointing to underlying biosimilar strength that supports upside. Article Title
• Positive Sentiment: Coverage pieces highlight Alvotech’s ongoing execution in the biosimilar market and argue for continued growth potential, which could be supportive if revenue trends and margin progress continue. Alvotech Charts Course for Continued Growth in Biosimilar Market
• Positive Sentiment: Northland Securities published commentary on Alvotech’s FY2026 results (revenue beat but EPS miss in recent quarter), providing additional analyst attention that may help reprice the stock as investors parse forward guidance and pipeline milestones. Northland Securities Comments on Alvotech FY2026 Earnings
• Neutral Sentiment: Short-interest reports are inconsistent: one clean print shows a meaningful decline to ~2.46M shares short (≈0.8% of shares) as of March 13 with a short-interest ratio ~3.7 days — a modest short base. However, multiple March 23–24 data entries report “0 shares” (likely reporting glitches), so short-interest trends should be treated cautiously.
• Negative Sentiment: Barclays cut its price target from $5 to $4 and maintained an Underweight rating, a bearish signal that likely pressured the stock alongside broader downgrades. Article Title
• Negative Sentiment: Analyst target reductions overall (UBS lowered its PT despite keeping a Buy; Barclays trimmed target and kept Underweight) increase near-term uncertainty and likely contributed to the share decline as investors weigh regulatory risk, earnings misses, and execution against long-term biosimilar opportunity. Alvotech: Regulatory Setbacks Priced In…

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its holdings in shares of Alvotech by 1,707.7% in the 4th quarter. Millennium Management LLC now owns 357,176 shares of the company’s stock valued at $1,832,000 after buying an additional 337,417 shares during the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new position in Alvotech during the second quarter worth $1,782,000. Norges Bank acquired a new position in Alvotech during the second quarter worth $1,656,000. Goldman Sachs Group Inc. raised its position in Alvotech by 88.8% during the fourth quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock worth $1,331,000 after acquiring an additional 122,089 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Alvotech by 2.7% during the third quarter. Vanguard Group Inc. now owns 4,348,151 shares of the company’s stock worth $35,481,000 after acquiring an additional 114,255 shares in the last quarter.

Alvotech Stock Down 6.0%

The business’s 50 day simple moving average is $4.46 and its 200 day simple moving average is $5.77. The stock has a market cap of $943.63 million, a price-to-earnings ratio of 31.30 and a beta of 0.16.

Alvotech (NASDAQ:ALVO) last issued its earnings results on Wednesday, March 18th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of $0.13 by ($0.50). Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%.The business had revenue of $173.20 million for the quarter, compared to the consensus estimate of $162.20 million. Equities research analysts forecast that Alvotech will post -0.07 earnings per share for the current fiscal year.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).